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ABSTRACT 
Aim: This study investigated the prevalence of extraintestinal manifestations (EIM) in 
paediatric celiac disease and their associations with other disease features. 
Methods: Researchers at the University of Tampere, Finland, compared EIM in 511 children 
diagnosed with celiac disease from 2003-2014 and 180 diagnosed with functional 
gastrointestinal disorders from 2007-2013. Disease severity and dietary responses were also 
compared between celiac children diagnosed by screening (n=146) or because of EIM 
(n=116) or gastrointestinal (n=249) symptoms. 
Results: Celiac patients had more EIM (62%) than those with functional disorders (33%). 
The most common EIM in celiac children were poor growth (27%) and anaemia (18%). 
Children with celiac disease often showed fatigue (8%) and symptoms affecting the skin 
(15%), nervous system (9%) and joints (6%). Celiac patients with EIM as their main clinical 
presentation had more severe symptoms and histological damage at diagnosis than those with 
gastrointestinal presentation and screen-detected cases. The subgroups did not differ with 
regard to other clinical and laboratory parameters and dietary adherence. Concomitant EIM 
were also common in children diagnosed because of gastrointestinal presentation (60%) and 
by screening (37%). 
Conclusion: EIM were common in celiac disease and associated with more severe clinical 
and histological presentation. 
Keywords: Celia disease, Extraintestinal manifestations, Histology, Paediatric, Serology, 
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Key notes 
• This study investigated the prevalence of extraintestinal manifestations (EIM) and 
their association with other disease features in paediatric celiac disease. 
• We found that EIM were common in children with untreated celiac disease and their 
presence was associated with more severe clinical and histological presentation. 
• In addition, the 511 children with celiac disease had higher levels of EIM than the 180 
children with functional gastrointestinal disorders we studied. 
 
 
 
  
4 
 
INTRODUCTION  
The classical clinical presentation of celiac disease is early-onset diarrhoea and 
malabsorption, with other common gastrointestinal symptoms being abdominal pain, bloating, 
nausea and constipation. Despite this, patients may also present with a variety of 
extraintestinal manifestations (EIM), for example poor growth, increased liver enzymes, 
dermatitis herpetiformis or other rashes, arthritis and various neurological symptoms (1-3). It 
has been suggested that these atypical symptoms may occur even more frequently than the 
classical gastrointestinal presentation (1,2,4).  
Although many EIM of celiac disease have been known for some time (5), 
their actual prevalence is poorly defined. It is even more unclear whether the presence of such 
symptoms affects the severity of histological damage and other characteristics of celiac 
disease at the time of diagnosis. The great majority of celiac disease sufferers currently 
remain either unrecognised or there is an unacceptably long diagnostic delay (6). A better 
understanding of the heterogeneous EIM would increase diagnostic efficacy and prevent the 
unnecessary burden, and possibly the severe complications, associated with unrecognised 
celiac disease.  
The aim of this study was to investigate the prevalence of EIM symptoms in 
children with celiac disease. In order to benchmark the observed prevalence, they were 
compared with children suffering from functional gastrointestinal symptoms. In addition, we 
sought to establish whether the main clinical presentation of celiac disease, namely 
extraintestinal symptoms versus gastrointestinal symptoms and screen-detected symptoms, 
affected other disease features and the patients’ responses to a gluten-free diet. 
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PATIENTS AND METHODS 
Study subjects and design 
The study was carried out in Finland, at the Center for Child Health Research, University of 
Tampere and Tampere University Hospital, and in the Department of Pediatric 
Gastroenterology of Tampere University Hospital. We included all children under the age of 
18 diagnosed with celiac disease from 2003-2014 or functional gastrointestinal disorder from 
2007-2013. Children with an uncertain diagnosis or potential celiac disease were excluded 
from further analyses. Medical information was collected from the hospital patient records 
and from our regularly updated paediatric research database, which has previously been 
described (4). From 2012 onwards the celiac disease patients were enrolled as part of a 
prospective patient collection, but all the other study data were collected retrospectively. 
The diagnosis of celiac disease was based on the demonstration of small-bowel 
mucosal villous atrophy and crypt hyperplasia (7). Functional gastrointestinal disorder was 
diagnosed in children who had undergone meticulous clinical and laboratory investigations 
and gastrointestinal endoscopy. These included intestinal biopsies because of undefined 
abdominal symptoms, such as pain, dyspepsia and nausea, without findings suggestive of any 
organic disease (8). 
Clinical information, including the presence of EIM at diagnosis as reported by 
the attending physician, was collected on all the children. Celiac patients also underwent 
analyses of the disease-specific transglutaminase 2 and endomysial antibodies and other 
relevant laboratory parameters, as described below. Furthermore, the presence of concomitant 
associated conditions such as type 1 diabetes mellitus, autoimmune thyroidal disease and 
Down syndrome were noted. After these analyses, children with celiac disease were further 
divided into those diagnosed because of extraintestinal or gastrointestinal manifestations 
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symptoms and those who were detected during at-risk group screening. The groupings were 
carried out on the basis of the original notes in the medical record. These three subgroups 
were compared in terms of clinical characteristics, histology and serology and adherence and 
responses to a gluten-free diet. 
The collection of patient information from the medical records was approved by 
the Department of Pediatrics, Tampere University Hospital. In addition, prospective patient 
enrolment and data gathering were accepted by the Ethics Committee of the Pirkanmaa 
Hospital District. All participating children and, or, their parents provided written informed 
consent, depending on the patient’s age. 
 
Presence of EIM 
The possible presence of EIM was recorded for all study children. These features included 
skin symptoms, such as dermatitis herpetiformis, atopic dermatitis, erythema nodusum, 
acanthosis nigricans or an unspecified rash; anaemia; poor growth and dental enamel defects 
and neurological symptoms, such as migraine or other headaches. They also included 
worsening of epilepsy or gluten ataxia; arthritis or other joint symptoms; recurrent aphtous 
ulcers and other mouth symptoms, hypertransaminasemia, defined as alanine 
aminotransferase > 40 U/l; fatigue; eye symptoms, such as episcleritis or uveitis, and other 
celiac disease associated extraintestinal symptoms as described in the literature (1,2,9). 
Anaemia was defined based on age and gender-specific reference values, as previously 
described in detail (10). Poor growth was defined as an abnormal deceleration of growth 
compared with age and gender-specific reference charts or growth below the expected target 
height, as previously described in detail (3). This definition is meant to be a sensitive 
screening tool for early detection of possibly treatable problems and does not necessary mean 
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that the child will have abnormal growth. 
The severity of symptoms at diagnosis was determined on basis of the clinical 
picture as reported by the clinician. Mild was occasional disturbing symptoms, moderate was 
symptoms that were more distracting or frequent and severe symptoms were those that 
seriously disturbed daily life. 
 
Celiac disease serology and laboratory parameters 
Serum transglutaminase 2 antibodies were measured using an conventional ELISA (Phadia 
AB, Uppsala, Sweden) before 2011 or an automatised human recombinant-based EliA assay 
(Phadia AB, Uppsala, Sweden) from 2011 onwards. In our laboratory a transglutaminase 2 
value of ≥ 7 U/l is considered positive and the maximum reported value is 120 U/l. Serum 
endomysial were measured by indirect immunofluorescence using human umbilical cord as a 
substrate, as previously described (11). An endomysial dilution of 1: ≥ 5 was considered 
positive and positive sera were further diluted from 1:50 to 1:4000 until negative. 
The following laboratory values measured from blood samples at the time of 
celiac disease diagnosis were collected from each child when available: haemoglobin (g/l), 
mean corpuscular volume (fl), total iron (µmol/l), alanine aminotransferase (U/l), ferritin 
(µg/l), transferrin receptor 1 (mg/l), alkaline phosphatase (U/l), albumin (g/l), thyroid-
stimulating hormone (mU/l) and thyroxin (pmol/l).  
Small-bowel mucosal morphology 
At least four forceps biopsy samples were taken from the distal duodenal mucosa and from 
the duodenal bulb from 2012 onwards in all cases were celiac disease was suspected. The 
specimens were further processed and analysed in the hospital pathology unit. Only correctly 
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oriented specimens were accepted for further microscopic analyses. If there was poor 
orientation, new cuttings were requested according to our standard operating procedures. In 
the present study the severity of the mucosal damage was categorised, based on the hospital 
pathologist´s original grading, into partial, subtotal and total villous atrophy.  
Adherence and responses to a gluten free diet 
All celiac disease patients were placed on a gluten-free diet within 1-4 weeks of diagnosis, 
under the supervision of a qualified dietician. Adherence to the diet were categorised as strict 
diet, occasional lapses and no diet and evaluated during follow-up visits, based on family 
interviews and the results of serology, as previously described (14). The patient’s response to 
the diet was also assessed and classified. A response was defined as the alleviation of 
symptoms and normalised or constantly decreasing celiac autoantibody levels and no 
response was defined as persistent symptoms and, or, positive autoantibodies. 
Statistical analysis 
All statistical analyses were performed using SPSS for Windows, version 21.0 (IBM, New 
York, USA. Differences between the groups were compared by the Mann-Whitney U test, the 
Kruskal-Wallis test, Pearson’s chi-square and Fisher's exact test. Data are expressed as either 
medians with upper and lower quartiles or as percentages. A p value of < 0.05 was considered 
significant.  
 
RESULTS 
The final study cohort comprised 511 children with celiac disease and 180 with functional 
gastrointestinal disorders. The celiac patients were younger than those with functional 
gastrointestinal disorders, with a median age of 7.6 (4.8-11.6 years) versus 10.6 (6.8-13.7) 
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years, and they were more likely to be girls (65 versus 53%) (Table 1). EIM were present 
almost twice as often in celiac disease than functional disorders (62 versus 33%) (Table 1). 
The most common EIM in celiac disease were poor growth (27%), anaemia (18%) and skin 
symptoms (15%) and other frequent presentations were hypertransaminasemia (9%), 
neurological symptoms (9%), fatigue (8%) and joint symptoms (6%). Dermatitis 
herpetiformis, a well-known skin manifestation of celiac disease, was found in eight (1.6%) 
children with celiac disease. Recurrent aphtous ulcers were rare in both groups and dental 
enamel defects were found only in three children with celiac disease. A variety of other EIM 
were reported in celiac disease patients (Table 1). 
The main reason for suspected celiac disease was EIM in 116 (23%) patients 
and gastrointestinal presentation in 249 (49%) patients. A further 146 (29%) patients were 
detected during screening of high-risk groups. The most common indications for screening 
were a family risk of celiac disease (42%) and previously diagnosed type 1 diabetes (12%). 
Concomitant EIM were also common in the two latter groups and these patients displayed 
particularly dermatological and neurological symptoms, poor growth, fatigue, anaemia and 
hypertransaminasemia (Table 2).  
We also analysed the children with celiac disease based on whether they were 
diagnosed by EIM, gastrointestinal symptoms or screening. This showed that with children 
with EIM as the main presentation had more severe villous atrophy than those diagnosed by 
screening or gastrointestinal symptoms (Fig 1a), while screen-detected children had the 
highest levels of haemoglobin, albumin and transglutaminase 2 (Table 3). There was also a 
clinically small, but statistically significant (p=0.032), difference in the median haemoglobin 
values between the three sub-groups (123, 24 and 126 g/l, respectively). The three subgroups 
did not differ with regard to other laboratory values, growth parameters and age (Table 3), 
gender distribution (girls 64%, 67% and 62%, p=0.550) and prevalence of celiac disease-
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associated conditions (10%, 10% and 17%, p=0.114). The severity of symptoms prior to 
diagnosis was considered mild in 22% and moderate or severe in 78% of children with EIM 
presentation and the corresponding figures in those with gastrointestinal presentation was 
53% and 47% (p<0.001). In addition, 45% of the screen-detected children reported mild and 
14% moderate symptoms.  
Children in all three celiac disease subgroups showed excellent and practically 
equal adherence to the gluten-free diet (Fig 1b). Likewise, the beneficial response to dietary 
treatment was comparable between the groups: EIM 98%, gastrointestinal 96% and screen-
detected 97% (p=0.556). 
 
DISCUSSION 
There were two main findings in the present study. First, we observed that EIM were clearly 
overrepresented in children with untreated celiac disease compared to children with functional 
gastrointestinal disorders. Second, the presence of EIM at celiac disease diagnosis was 
associated with a more severe clinical and histological presentation.  
We found that particularly common EIM in children with celiac disease were 
poor growth, anaemia and skin symptoms. In fact, poor growth was noted in almost one-third 
of the celiac patients at diagnosis. This was in line with the findings of Jericho et al (12), who 
reported a prevalence of 33% for growth failure in paediatric celiac disease. On the other 
hand, markedly lower (13-15) and higher (16) frequencies have been reported by other 
studies. Apart from differences in study design and population, the inconsistent results might 
be, at least partly, explained by variable definitions. We defined poor growth using specific 
Finnish growth references, which have all been well validated and may even lead to improved 
celiac disease diagnostics (17). However, these screening charts are more sensitive for growth 
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variations than the more widely used World Health Organization criteria, which explains the 
unusually high number of children with abnormal growth in the functional gastrointestinal 
disorder group. This may also complicate comparisons with previous studies. Poor growth 
was classified here as an EIM because it might also be caused by other pathophysiological 
mechanisms than just malabsorption (2). 
The second most common EIM in celiac disease was anaemia. Although the 
incidence was about as common as observed in our other recent studies (4,10), the prevalence 
of anaemia was similar to poor growth in that it was markedly lower in this study than in most 
previous reports (13,15,18). One explanation could be that, overall, nutritional status is good 
in Finnish children and anaemia and iron deficiency are rare. Moreover, the presence of 
anaemia at the time of celiac disease diagnosis is known to be associated with a severe 
clinical and histological presentation and long diagnostic delay (10,18) and these are both less 
frequent in Finland than in many other countries (4). Similarly as with growth failure, the 
definition of anaemia as an EIM can be debated, but the concept is based on evidence that 
anaemia in celiac disease is not necessarily associated with the degree of intestinal 
malabsorption (2,10,19). Besides iron deficiency, it can also be caused factors such as  
chronic inflammation and bone marrow suppression (20). In general, the pathophysiology of 
EIM in celiac disease is poorly known, but there are probably several mechanisms, such as 
chronic inflammation, nutritional deficiencies and hormonal changes (2). Furthermore, 
autoantibodies targeted, for example, against the brain in gluten ataxia (21) and the bones in 
osteoporosis (22) may not be just surrogate markers, but may also play a role in the 
pathogenesis. 
Skin manifestations were another common finding in untreated celiac disease. 
We found that eight (1.6%) children had dermatitis herpetiformis, a well-known EIM of 
celiac disease, whereas the association between other rashes and celiac disease is less clear. 
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Unspecific skin symptoms, such as viral exanthemas and atopic eczema, are rather common 
in children, but the overrepresentation of rashes in celiac children compared to those with 
functional symptoms in this study suggests that these were indeed related to celiac disease. 
The relative rarity of dermatitis herpetiformis in the children in our study was in accord with 
the latest evidence (23). There have been a dearth of studies regarding the prevalence of other 
rashes in celiac disease patients, but two papers have reported figures comparable to ours 
(12,14). 
Of the other EIM, neurological and joint symptoms, fatigue and 
hypertransaminasemia were particularly frequent in our celiac disease patients. The 
prevalence of neurological symptoms was consistent with findings from Finland and Italy 
(13,15) and they were reported in up to 51% of Israeli children with celiac disease (14). 
Fatigue and joint symptoms were more common in children with celiac disease than in those 
with functional disorders, but less common than reported by other authors (18,24,25). In our 
earlier study, 15% of children with untreated celiac disease had elevated alanine 
aminotransferase values (26) and even higher rates have been reported (27). Nevertheless, this 
study used a higher cut-off for increased values than our previous study, since mild 
hypertransaminasemia usually has no major clinical significance (26). In contrast to the 
above-mentioned symptoms, mouth and teeth findings were quite rare. The prevalence of 
enamel defects and aphtous ulcers has also varied substantially in other studies, probably due 
to their vague nature and difficult definition (13,28). Altogether, the marked variations 
between studies in the prevalence of extraintestinal symptoms emphasises the need for 
prospective studies.  
We found that children with EIM had more severe duodenal lesions than those 
with gastrointestinal presentation. The histology has not previously been studied in these 
circumstances, but Mubarak et al (18) reported that EIM were more frequent in subjects with 
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high transglutaminase 2 values. The surprising presence of the highest antibody levels in the 
screen-detected children might have been due to clinicians’ reluctance to perform gastroscopy 
in these often asymptomatic patients with low positive serology. In any case, the association 
between clinical and histologic presentation in celiac disease indicates a pathogenic link. In 
inflammatory bowel disease, for instance, antigen cross-reactivity, malabsorption and certain 
human leukocyte antigen phenotypes are thought to be associated with the presence of EIM 
(29), while there a is lack of similar studies in celiac disease. Aside from the previously 
mentioned factors in inflammatory bowel disease, the relationship between intestinal 
microbiota and EIM is particularly interesting (30). Even though EIM associated with more 
severe presentation in both conditions, celiac disease patients generally have a general better 
prognosis since the pathogenic process can be reversed by specific treatment. 
The main strengths of the present study were the large cohorts of representative 
celiac disease patients and controls and the wide range of clinically relevant data available on 
each child. We recognise that there were also several limitations. The main limitation was the 
retrospective design and lack of systematic questionnaires for the evaluation of symptoms. 
This might have led, for example, to us underestimating mild or vague symptoms such as 
enamel defects, aphtous stomatitis and fatigue. Retrospective grouping of the study children 
to those with EIM or gastrointestinal presentation was challenging and inevitably subjective, 
particularly if a patient was suffering from more than one symptom simultaneously. The lack 
of prospective data might also have affected the assessment of dietary responses, as 
physicians may have focused mostly on alleviating classical gastrointestinal symptoms. 
Moreover, we were not able to find out whether the symptoms disappeared totally when the 
children were on a gluten-free diet, which would have further supported the causal 
relationship between EIM and celiac disease. The retrospective design led to missing growth 
data and laboratory values from some of the patients, which may have caused selection bias. 
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We also were not able to evaluate the exact diagnostic latency in celiac disease. This would 
have been important, as it is possible that the frequency of EIM was affected by the duration 
of untreated disease. In addition, the possibility that asymptomatic children with low positive 
serology were less frequently biopsied might have biased the differences between screen-
detected and symptomatic patients. Finally, the lack of a standardised international definition 
of extraintestinal symptoms makes comparing our data with other studies challenging.  
 
CONCLUSION 
We found that EIM were common in children with celiac disease and were 
associated with a more severe clinical and histological presentation. It is, therefore, important 
that clinicians consider the possibility of celiac disease as a cause for variable EIM and to 
specifically consider their presence in newly diagnosed celiac patients. In the future, large 
multi-centre prospective studies would provide even more robust information on the 
prevalence of EIM in celiac disease. 
 
Abbreviations 
EIM, extraintestinal manifestations   
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Figure legend 
 
Figure 1. Severity of small-bowel mucosal villous atrophy at diagnosis (A) and adherence to 
gluten free diet (B) in 511 children with celiac disease divided into three subgroups according 
to the main clinical presentation at the time of diagnosis. 
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 Table 1. Demographic data and prevalence of extraintestinal manifestations at the time of diagnosis in 
children with celiac disease, inflammatory bowel disease and functional gastrointestinal disorder 
 n Celiac disease n=511 
n Functional disorder 
n=180 P value 
Age, median (quartiles), years 511 7.6 (4.8, 11.6) 180 10.6 (6.8, 13.7) <0.001 
Girls, % 511 65 179 53 0.003 
Extraintestinal manifestations, %      
Skin symptoms1 511 15 180 4 <0.001 
Anemia 459 18  103 5 0.001 
Poor growth 511 27 180 9 0.000 
Enamel defects 511 1 180 0 0.303 
Neurological symptoms2 511 9 180 3 0.006 
Joint symptoms 511 6 180 2 0.016 
Recurrent aphtous ulcers 511 2 180 3 0.476 
Hypertransaminasemia 152 9 63 3 0.159 
Fatigue 511 8 180 3 0.022 
Other3 511 5 180 12 0.001 
Total4  511 62 180 33 <0.001 
1Dermatitis herpetiformis, atopic dermatitis, acanthosis nigricans, undefined rash 
2Headache, worsening of epilepsy or migraine, attention deficit/hyperactivity disorder-type symptoms, 
learning or communication difficulties, motor disorders 
3Mouth/tongue pain, brittle nails, alocipea, epistaxis, shortness of breath, osteopenia, depression 
4One or more extraintestinal symptom 
 
Table 2. Prevalence of extraintestinal manifestations at the time of diagnosis in 511 children with celiac disease 
divided according to the main clinical presentation.  
  Main mode of presentation at diagnosis  
  Extraintestinal n=116 
 Gastrointestinal 
n=249 
 Screen-detected 
n=146 P value 
Extraintestinal manifestation n % n % n %  
Skin symptoms1 116 19 249 15 146 13 0.400 
Anemia 105 35 213 16 141 7 <0.001 
Poor growth 116 56 249 21 146 14 <0.001 
Enamel defects 116 1 249 1 146 0 0.605 
Neurological symptoms2 116 10 249 10 146 8 0.763 
Joint symptoms 116 15 249 5 146 1 <0.001 
Aphtous ulcers 116 4 249 2 146 1 0.143 
Hypertransaminasemia 46 13 80 6 26 8 0.421 
Fatigue 116 16 249 9 146 1 <0.001 
Other3 116 10 249 4 146 2 0.014 
Total4 116 100 249 60 146 37 <0.001 
1Dermatitis herpetiformis, atopic dermatitis, acanthosis nigricans, undefined rash 
2Headache, worsening of epilepsy or migraine, attention deficit/hyperactivity disorder-type symptoms, learning 
or communication difficulties, motor disorders 
3Mouth/tongue pain, brittle nails, alocipea, epistaxis, shortness of breath, osteopenia, depression 
4One or more extraintestinal symptom 
 
 Table 3. Age, growth data, serum autoantibodies and selected laboratory values at the time of diagnosis in 511 children with celiac disease divided 
according to the main clinical presentation. 
  Extraintestinal n=116   
Gastrointestinal 
n=249   
Screen-detected 
n=146   
 n1 Median (Q1, Q3) n1 Median (Q1, Q3) n1 Median (Q1, Q3) P value 
Age, years 116 10.0 (4.6, 12.3) 249 7.4 (5.0, 11.0) 146 7.0 (4.1, 11.6) 0.092 
Height, SD 63 -0.2 (-1.0, 0.7) 110 0.1 (-0.7, 1.0) 87 0.3 (-0.5, 1.2) 0.173 
Body mass index, kg/m2 45 16.4 (14.9, 18.6) 90 16.3 (15.0, 18.5) 67 16.3 (15.0, 18.0) 0.891 
EmA, titer 79 1:500 (1:100, 1:2000) 159 1:500 (1:100, 1:1000) 97 1:500 (1:100, 1:2000) 0.146 
TG2ab, U/l 38 51 (14, 80) 116 43 (17, 80) 80 65 (25, 115) 0.030 
Hemoglobin, g/l 87 124 (105, 131) 174 123 (114, 131) 81 126 (121, 135) 0.032 
Ferritin, µg/l 32 12.0 (7.0, 23.0) 52 13.0 (6.3, 22.8) 25 10.0 (6.0, 17.0) 0.725 
Transferrin receptor 1, mg/l 27 4.4 (3.5, 7.7) 41 4.2 (3.4, 5.7) 18 4.5 (3.1, 6.1) 0.604 
Albumin, g/l 23 38.0 (37.0, 41.0) 52 38.0 (35.5, 40.0) 19 41.0 (38.0, 42.0) 0.051 
Alkaline phosphatase, U/l 31 179 (136, 245) 56 212 (168, 238) 19 194 (161, 226) 0.497 
Alanine aminotransferase, U/l 46 21.5 (16.0, 30.3) 79 20.0 (15.0, 24.0) 25 20.0 (16.0, 25.50) 0.292 
TSH, mU/l 48 2.7 (1.7, 3.7) 74 2.4 (1.6, 3.1) 41 2.0 (1.5, 3.2) 0.138 
Thyroxine, pmol/l 29 14.4 (12.6, 16.2) 26 14.7 (13.1, 16.2) 10 15.2 (14.0, 18.0) 0.605 
Q1, Q3 = lower and upper quartiles; EmA = endomysial antibodies; TG2ab = transglutaminase 2 antibodies; TSH = thyroid stimulating hormone 
1Data available 
